# Efficacy of Rostafuroxin in the Treatment of Essential Hypertension

> **NCT00415038** · PHASE2 · COMPLETED · sponsor: **sigma-tau i.f.r. S.p.A.** · enrollment: 438 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Rostafuroxin
- **DRUG:** Rostafuroxin
- **DRUG:** Rostafuroxin
- **DRUG:** Rostafuroxin
- **DRUG:** Rostafuroxin

## Key facts

- **NCT ID:** NCT00415038
- **Lead sponsor:** sigma-tau i.f.r. S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2007-04
- **Final completion:** 2007-08
- **Target enrollment:** 438 (ACTUAL)
- **Last updated:** 2011-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00415038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00415038, "Efficacy of Rostafuroxin in the Treatment of Essential Hypertension". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00415038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*